Antibodies with two distinet binding specificities have great potential for a wide range of
clinical applications as targeting agents for in vitro and in vivo immunodiagnosis and …

Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA
or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the …

Bispecific antibodies are unique in the sense that they can bind simultaneously two different
antigens. This property enables the development of therapeutic strategies that are not …

Bispecific antibodies recognizing two different antigens present on different cells have been
developed for cellular cancer therapy in which cytotoxic effector cells are recruited to tumor …

Gene amplification, over-expression, and mutation of growth factors, or the receptors
themselves, causes increased signaling through receptor kinases, which has been …

Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …

Bispecific antibodies are immunoglobulin molecules with two different antigen binding sites.
They can be prepared either by chemical crosslinking of immunoglobulins with different …

Bispecific antibodies have immense potential as reagents and in medicine. Until recently,
they were made by combining monoclonal antibodies of two different specificities in vitro, or …

The binding of at least two molecular targets simultaneously with a single bispecific antibody
is an attractive concept. The use of bispecific antibodies as possible therapeutic agents for …

Bispecific antibodies--molecules combining two different antigenic specificities--are currently
being developed as new agents for immunotherapy and for basic studies in cell biology …